Rita Paschal, MD
Hematology & Oncology · Jacksonville, FLNPI 1356498158
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.6%), education and speaking fees — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Genentech, Inc. at 29.2% of the total. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 7 payments — averaging $78.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$160
- AstraZeneca$150
- Amgen$125
- Octapharma USA, Inc.$96
- Sanofi$19
Across 18 payments — averaging $9742.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$152K
- Sanofi US Services Inc.$24K
What the payments were for
- Speaking & faculty fees$15027%
- Food & beverage$24044%
- Education$16029%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 3 | $160 |
| AstraZeneca | 1 | $150 |
| Amgen | 1 | $125 |
| Octapharma USA, Inc. | 1 | $96 |
| Sanofi | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
How this compares
$550 in reported general payments places this provider in the 20th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 30 | $575,926 |
| PromactaEltrombopag Olamine | 33 | $341,930 |
| EliquisApixaban | 136 | $93,077 |
| XareltoRivaroxaban | 27 | $26,547 |
| Enoxaparin Sodium | 29 | $10,075 |
| Hydroxyurea | 128 | $3,944 |
| Prednisone | 31 | $242 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $218 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.